PMID- 34677245
OWN - NLM
STAT- MEDLINE
DCOM- 20211027
LR  - 20211027
IS  - 1718-7729 (Electronic)
IS  - 1198-0052 (Print)
IS  - 1198-0052 (Linking)
VI  - 28
IP  - 5
DP  - 2021 Sep 30
TI  - Expression of Senescence and Apoptosis Biomarkers in Synchronous Bilateral Breast 
      Cancer: A Case Report.
PG  - 3836-3845
LID - 10.3390/curroncol28050327 [doi]
AB  - BACKGROUND: Synchronous bilateral breast cancer (SBBC) provides a special 
      condition where two independent breast tumors are exposed to cancer 
      pharmacotherapy within a uniform pharmacokinetic milieu. Both senescence and 
      apoptosis are established responses to therapy; however, they have potentially 
      variable contributions to the overall outcome of treatment, which are yet to be 
      determined. METHODS: In this report, we describe the clinicopathological picture 
      of two SBBC cases that received standard anticancer treatment and assess their 
      expression profile of several molecular hallmarks of senescence and apoptosis. 
      RESULTS: Our analysis identified that synchronous tumors have variable expression 
      profiles of both senescence- and apoptosis-associated biomarkers, despite 
      comparable pathological responses to neoadjuvant chemotherapy and current 
      survival rates. CONCLUSIONS: Our results highlight the variable expression of 
      senescence- and apoptosis-associated markers in breast tumors (despite the shared 
      somatic genetic background) and invites a large-scale assessment of both 
      senescence and apoptosis in breast cancer tissue in vivo and their contribution 
      to the pathological response and overall survival.
FAU - Saleh, Tareq
AU  - Saleh T
AD  - Department of Basic Medical Sciences, Faculty of Medicine, The Hashemite 
      University, Zarqa 13133, Jordan.
FAU - El-Sadoni, Mohammed
AU  - El-Sadoni M
AD  - Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, 
      The University of Jordan, Amman 11942, Jordan.
FAU - Alhesa, Ahmad
AU  - Alhesa A
AD  - Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, 
      The University of Jordan, Amman 11942, Jordan.
FAU - Awad, Heyam
AU  - Awad H
AD  - Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, 
      The University of Jordan, Amman 11942, Jordan.
FAU - Jaradat, Mahmoud
AU  - Jaradat M
AD  - Department of General Surgery, Jordanian Royal Medical Services, Amman 11942, 
      Jordan.
FAU - Al-Hazaimeh, Mohammad
AU  - Al-Hazaimeh M
AD  - Department of General Surgery, Jordanian Royal Medical Services, Amman 11942, 
      Jordan.
FAU - Dawoud, Rand
AU  - Dawoud R
AD  - Department of Basic Medical Sciences, Faculty of Medicine, The Hashemite 
      University, Zarqa 13133, Jordan.
FAU - Mryyian, Amel
AU  - Mryyian A
AD  - Department of Basic Medical Sciences, Faculty of Medicine, The Hashemite 
      University, Zarqa 13133, Jordan.
FAU - Azab, Bilal
AU  - Azab B
AD  - Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, 
      The University of Jordan, Amman 11942, Jordan.
AD  - Department of Pathology and Cell Biology, Columbia University Irving Medical 
      Center, New York, NY 10032, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210930
PL  - Switzerland
TA  - Curr Oncol
JT  - Current oncology (Toronto, Ont.)
JID - 9502503
RN  - 0 (Biomarkers)
SB  - IM
MH  - Apoptosis/genetics
MH  - Biomarkers
MH  - *Breast Neoplasms/drug therapy/genetics
MH  - Female
MH  - Humans
MH  - *Neoplasms, Multiple Primary
PMC - PMC8535022
OTO - NOTNLM
OT  - BCL-2
OT  - apoptosis
OT  - bilateral
OT  - breast cancer
OT  - chemotherapy
OT  - p16INK4a
OT  - senescence
OT  - synchronous
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2021/10/23 06:00
MHDA- 2021/10/28 06:00
PMCR- 2021/09/30
CRDT- 2021/10/22 12:17
PHST- 2021/08/31 00:00 [received]
PHST- 2021/09/28 00:00 [accepted]
PHST- 2021/10/22 12:17 [entrez]
PHST- 2021/10/23 06:00 [pubmed]
PHST- 2021/10/28 06:00 [medline]
PHST- 2021/09/30 00:00 [pmc-release]
AID - curroncol28050327 [pii]
AID - curroncol-28-00327 [pii]
AID - 10.3390/curroncol28050327 [doi]
PST - epublish
SO  - Curr Oncol. 2021 Sep 30;28(5):3836-3845. doi: 10.3390/curroncol28050327.